Hilleman Laboratories Opens US$20 Million Vaccine Facility in Singapore

Published 2026-10-29

Hilleman Laboratories, a non-profit organisation that develops affordable vaccines and biologics for infectious diseases with unmet medical needs, has officially opened a new US$20 million facility in Singapore. The new site is designed to strengthen the resilience of vaccine manufacturing in the region and around the world.

The organisation's mission is to make vaccines more affordable for people who need them most. By investing in local production, Hilleman Laboratories aims to help ensure that vaccines can be made quickly and reliably, even during times of global supply pressure. Singapore was chosen as the location for the facility because of its strong life sciences sector and its well-developed infrastructure for pharmaceutical production.

The opening is also a sign of Singapore's continued role as a hub for biomedical research and manufacturing. The Economic Development Board (EDB), the government agency that promotes investment in the country, has highlighted such projects as part of its efforts to attract companies working in healthcare and advanced manufacturing. Projects like this can create jobs and build skills in areas such as biologics production and quality control.

For Singapore residents, the facility shows how the country is working to become more self-reliant in essential healthcare products. Vaccine manufacturing is a complex process that requires specialised equipment and highly trained staff, so the new facility may help to build expertise that benefits the local workforce in the years ahead.

Sources: Singapore Economic Development Board (EDB)

More Singapore news

All Singapore news · News by country